Key result
Trastuzumab and lapatinib exert distinct effects on calcium cycling and HER2 expression in stem cell-derived cardiomyocytes.
Why the study?
Trastuzumab and lapatinib both target the HER2 receptor but differ in their effects on cardiomyocytes, which requires investigation.
Do trastuzumab and lapatinib differ in effects on calcium cycling and HER2 expression in human embryonic stem cell-derived cardiomyocytes?
Do trastuzumab and lapatinib differ in effects on calcium cycling and HER2 expression in human embryonic stem cell-derived cardiomyocytes?
Answers are grounded in this paper and cite their sources.
Trastuzumab and lapatinib have differing effects on calcium cycling and HER2 expression in human embryonic stem cell-derived cardiomyocytes.
Introduction Trastuzumab (Herceptin), a humanized monoclonal antibody to HER2, and lapatinib (Tykerb), a small molecule tyrosine kinase inhibitor, both target the HER2 receptor which is highly expressed in 20-30% of breast cancers and other tumors. These agents have revolutionized breast cancer treatment [1,2]. Addition of trastuzumab to anthracycline- or taxane-based chemotherapy
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2013) studied this question. Trastuzumab and lapatinib demonstrate differing effects on calcium cycling and HER2 expression in human embryonic stem cell-derived cardiomyocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: